Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!


More On

Execs face tougher penalties for company wrongdoing

Government increasingly turning to “responsible corporate officer” doctrine

A little-known legal doctrine could mean trouble for executives of companies accused of wrongdoing.

Lately, the government is issuing stiffer penalties to executives through the “responsible corporate officer” doctrine, which holds officers who are in the position of responsibility to prevent offenses liable for a company’s misconduct even if they aren’t aware of the law-breaking.

Although prosecutors have used the doctrine sparingly over the past few decades, it is getting major play in recent high-profile health care prosecutions after a recent government report criticized the Food and Drug Administration’s handling of its criminal investigations.

On Nov. 21, three former executives of medical-device company Synthes Inc. were sentenced to between five and nine months in prison for their roles in illegal testing of a bone-cement product used to repair bones. The government claims the company attempted to hide its conduct after three patients treated with the product died during surgery.

Today, the Department of Health and Human Services is seeking to have an appeals court uphold a 12-year exclusion from government business for three former Purdue Pharma execs who pleaded guilty in 2007 to misbranding the painkiller OxyContin. Experts say the case could be an important test case in establishing how tough of penalties the government can issue without evidence that corporate officers knew of wrongdoing. Read Thomson Reuters for more about the case.

Ashley Post

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.